Aspirin and the elderly

Current Therapeutics

Volumn 37, Issue 9, 1996, Pages 29-33

  Silagy, Chris ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030491403     PISSN: 0311905X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971; 231: 232-5
2. UK-Study Group. United Kingdom transient ischaemia attack aspirin trial interim results. Br Med J 1988; 296: 316-20
3. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325: 1261-6
4. SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-9
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988; 334: 349-60
6. RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 71-2
8. Steering Committee of the Physicians' Health Study Research Group. Final report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-35
9. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6
10. Manson J, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521-7
11. Kalman R, Nieuwenhuis KH, de Groot PG, et al. Effects of low doses of aspirin, 10mg and 30mg daily, on bleeding time, thromboxane production and 6-keto-PGF1a excretion in healthy subjects. Thrombosis Research 1987; 45: 355-61
12. Seddon JM, Christen WG, Manson JE, et al. Low-dose aspirin and risks of cataract in a randomized trial of LS Physicians. Arch Ophthalmol 1991; 109: 252-5
13. Baldrati A, Cortelli P, Procaccianti G, et al. Propranolol and acetylsalicylic acid in migraine prophylaxis Acta Neurol Scand 1983; 67: 181-6
14. Buring JE, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264: 171 1-3
15. Masel BE, Chesson AL, Peters BH, et al. Platelet antagonists in migraine prophylaxis: a clinical trial using aspirin and dipyridamole. Headache 1980; 20: 13-8
16. O'Neil BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1978; 2: 1179-81
17. Ryan RE, Ryan RE Jr. The use of platelet inhibitors in migraine. Adv Neurol 1982; 33: 247-52
18. Thun MJ, Namboodiri MH, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6
19. Puganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 229: 1247-50
20. Lancaster T, Silagy CA. Aspirin and neoplasia of the digestive tract: Is there a chemoprotective effect? Digestive Diseases 1994; 12: 170-63